Insilico has a connected set of capabilities for adapting AI to scientific work. MMAI Gym develops specialized models; benchmarking helps researchers assess their performance; Generative Biologics, ...

• Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, ...

The convergence of frontier artificial intelligence, large-scale biological data, and pharmaceutical innovation is opening new possibilities for understanding human aging, predicting disease, and ...

Liquid AI and Insilico Medicine today announced a partnership that creates lightweight scientific foundation models for pharmaceutical research. The collaboration has produced LFM2-2.6B-MMAI (v0.2.1), ...

CAMBRIDGE, Mass. — Monday, September 7, 2026 (5AM EST) — Insilico Medicine (“Insilico”), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the ...

Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United States. The Phase I clinical trial aims to evaluate ...

Insilico Medicine has successfully created a unique approach to identifying potential therapeutic dual-purpose targets for aging and age-associated diseases with its PandaOmics software — an ...

Cambridge, MA, July 2, 2026 — Insilico Medicine (“Insilico” HKEX:3696), a leader in clinical-stage generative AI for drug discovery, today announced a strategic collaboration agreement with Takeda to ...

Insilico Medicine (HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, recently released its interim results report for 2026. The report shows that the ...

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly (“Lilly”) that the two parties will combine ...

The GENESIS-IPF Phase IIa study showed manageable safety and tolerability, with the 60 mg once-daily arm demonstrating mean forced vital capacity improvement of +98.4 mL at 12 weeks CAMBRIDGE, Mass., ...

Following a decade of exploration from the 2014 NVIDIA GTC to the PreciousGPT model series, Insilico Medicine presents the industry's first multi-agent Virtual Aging Cell(VAC) platform with biological ...